Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies

(2010) Stephen A. Beers et al.   SEMINARS IN HEMATOLOGY

Ten years of rituximab in NHL

(2009) Matthew C Winter et al.   Expert Opinion On Drug Safety

CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure

(2009) N. A. Johnson et al.   HAEMATOLOGICA

Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20

(2009) Jiamu Du et al.   MOLECULAR IMMUNOLOGY

Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide

(2008) Jiamu Du et al.   MOLECULAR IMMUNOLOGY